Back to Authors

Molina, Aurelia Alañón

0000-0002-7892-3492

A5101632874 | I111979921

Mayo Clinic

Northwestern University

Citations 4

Analysis of relationship between baseline body weight and efficacy/safety of yttrium 90 ( 90 Y) ibritumomab tiuxetan radioimmunotherapy in patients (pts) with non-Hodgkin's lymphoma (NHL)

Journal of Clinical Oncology | April 5, 2017 | Volume: 22 | Issue: 14_suppl | Pages: 6700-6700

10.1200/jco.2004.22.90140.6700

Low incidence of treatment-related myelodysplastic syndrome (tMDS) and acute myelogenous leukemia (tAML) in patients with non-Hodgkin's lymphoma (NHL) treated with ibritumomab tiuxetan

Journal of Clinical Oncology | April 5, 2017 | Volume: 22 | Issue: 14_suppl | Pages: 6696-6696

10.1200/jco.2004.22.90140.6696

Long-term follow-up of a phase I/II trial of radioimmunotherapy (RIT) with yttrium 90 ( 90 Y) ibritumomab tiuxetan for CD20+ B-cell non-Hodgkin's lymphoma (NHL)

Journal of Clinical Oncology | April 5, 2017 | Volume: 22 | Issue: 14_suppl | Pages: 6574-6574

10.1200/jco.2004.22.90140.6574

Yttrium 90 ibritumomab tiuxetan is safe and effective in older patients with relapsed or refractory NHL

Journal of Clinical Oncology | February 23, 2017 | Volume: 23 | Issue: 16_suppl | Pages: 6562-6562

10.1200/jco.2005.23.16_suppl.6562